Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 09/18 05:35:21 pm
78.14 EUR   --.--%
09/14UCB : Transparency notification BlackRock, Inc.
PU
09/14UCB : Threshold crossings
CO
09/13UCB : Data Presented at EADV 2018 Further Demonstrate the Value of &..
PU
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Business Summary
Logo UCB
Engages in the research, development, and commercialization of pharmaceutical and biotechnology products

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.

It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec.

The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Number of employees : 7 478 people.
Sales per Businesses
20162017Delta
EUR (in Million)%EUR (in Million)%
Cimzia1,30731.3%1,42431.4% +8.95%
Vimpat814.0019.5%976.0021.5% +19.9%
Keppra (Including Keppra XR)724.0017.3%778.0017.2% +7.46%
Other310.007.4%---
Neupro302.007.2%314.006.9% +3.97%
Zyrtec (including Zyrtec-D/Cirrus)140.003.4%103.002.3% -26.43%
Xyzal107.002.6%104.002.3% -2.8%
Venlaflaxine XR90.002.2%---
Nootropil46.001.1%44.001% -4.35%
Briviact18.000.4%87.001.9% +383.33%
Other Products--324.007.2%-
Designated hedges reclassified to net sales--28.000.6%-
Sales per Regions
20162017Delta
EUR (in Million)%EUR (in Million)%
United States1,85144.3%2,06945.7% +11.78%
Europe328.007.9%322.007.1% -1.83%
Other Countries319.007.6%371.008.2% +16.3%
Other292.007%295.006.5% +1.03%
Germany290.006.9%319.007% +10%
Japan268.006.4%292.006.4% +8.96%
Spain162.003.9%175.003.9% +8.02%
France161.003.9%161.003.6% 0%
Italy154.003.7%141.003.1% -8.44%
Belgium33.000.8%37.000.8% +12.12%
Managers
NameAgeSinceTitle
Jean-Christophe Tellier592011Chief Executive Officer & Executive Director
Evelyn du Monceau681984Chairman
Charl van Zyl, MBA512017Chief Operating Officer
Detlef Thielgen-2006Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich MD, PhD582006Chief Medical Officer & Executive Vice President
Dhavalkumar Patel, PhD-2017Chief Scientific Officer & EVP
Herman de Prins--Chief Information Officer
Norman J. Ornstein, PhD-2008Independent Director
Albrecht de Graeve632010Independent Director
Charles-Antoine Janssen-2001Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 194,505,658 116,459,777 59.9% 6,383,769 3.3% 59.9%
Shareholders
NameEquities%
Financière de Tubize SA 68,076,981 35.0%
Wellington Management Co. LLP 13,116,580 6.74%
UCB SA 6,729,677 3.46%
Wellington Management International Ltd. 5,118,453 2.63%
The Vanguard Group, Inc. 3,206,269 1.65%
BlackRock Fund Advisors 2,565,863 1.32%
Norges Bank Investment Management 2,377,002 1.22%
Schroder Investment Management Ltd. 1,552,620 0.80%
Lyxor International Asset Management SAS 1,189,152 0.61%
M&G Investment Management Ltd. 1,013,376 0.52%
Holdings
NameEquities%Valuation
UCB (UCB) 6,729,6773.46%616,689,161 USD
Dermira Inc (DERM) 1,841,2344.38%17,528,548 USD
Arix Bioscience Plc 3,869,9022.87%8,928,096 USD
Heidelberg Pharma AG (WL6) 1,131,1864.02%3,645,699 USD
Markets and indexes
- Euronext Brussels
- Compartiment A
- BEL 20 / Euronext 100, PEA
Stock Exchange Codes
- Bloomberg Code :  UCB:BB
- Reuters Code :  UCB.BR
- Datastream Code :  B:UCB
Company contact information
UCB
Allée de la Recherche 60
BE-1070 Bruxelles, Bruxelles-Capitale
Belgium

Phone : +32 (0)2 559 9999
Fax : +32 (0)2 559 9900
Internet : http://www.ucb.com
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
UCB18.07%17 772
JOHNSON & JOHNSON0.59%375 479
PFIZER18.75%252 129
NOVARTIS-1.14%215 800
ROCHE HOLDING LTD.-4.00%212 015
MERCK AND COMPANY25.15%187 284
AMGEN16.35%129 979
ABBOTT LABORATORIES18.57%118 715
ELI LILLY AND COMPANY25.16%113 531
SANOFI4.25%109 911
BRISTOL-MYERS SQUIBB COMPANY0.33%100 034
GLAXOSMITHKLINE12.42%97 077
ASTRAZENECA9.53%93 053
NOVO NORDISK A/S-9.91%90 881
BAYER-28.38%79 493
ALLERGAN PLC13.75%62 556
CELGENE CORPORATION-16.05%61 333
SHIRE15.08%53 399
ASTELLAS PHARMA INC34.62%33 545
CHUGAI PHARMACEUTICAL CO LTD17.50%33 325
TAKEDA PHARMACEUTICAL CO LTD-27.12%33 237
Connections : UCB
Belgian Luxembourg Chamber of Commerce for Russia & Belarus
The Campaign Legal Center
FBNet Belgium
European Federation of Pharmaceutical Industries & Assns
The Belgische Commissie Corporate Governance
The Innovative Medicines Initiative
Hoechst Marion Roussel, Inc.
Telenet NV
Pharmaceutical Research & Manufacturers of America
Drum Major Institute
U.S. Capitol Historical Society
Sibelco NV
Flanders-China Chamber of Commerce
The Conference Board, Inc.
SCR-Sibelco NV
Biotechnology Innovation Organization
Wallon Institute for Life Lead Sciences
Johann Wolfgang Goethe-Universität Frankfurt am Main
Telenet Group BVBA
Inflazome Ltd.
Concours Reine Elisabeth
Université Libre de Bruxelles
International Business Leaders Advisory Council
Kanyos Bio, Inc.
Anokion SA
KOIS India Investment Advisors Pte Ltd.
© 2018 People , Fundamentals and Ownership
© 2018 Cofisem